atezolizumab
Roche's Tiragolumab, Tecentriq Combo Misses Overall Survival Endpoint in PD-L1 Positive NSCLC Trial
The addition of tiragolumab to Tecentriq in patients with advanced PD-L1-high NSCLC failed to improve overall survival in a Phase III trial.
Roche Sees Strong Demand for Elevidys Gene Therapy Amid Steady Q3 Pharmaceutical Revenue Growth
Premium
About 500 children worldwide have received the gene therapy, including some families traveling abroad to gain access to it.
Roche Reports 5 Percent CER Growth in Pharmaceutical Sales Driven by Strong Phesgo Uptake
In the first half of the year, sales of the injectable formulation of HER2-targeted agent grew 60 percent at CER, compared to H1 2023.
The firm's long-term goal is to develop targeted cancer vaccines for patients at every stage of disease, including pre-cancer.
Roche Highlights Inavolisib Market Prospects as Q1 Revenues Fall 6 Percent on Currency Headwinds
Premium
The Swiss drugmaker expects a decision from the FDA on inavolisib as a treatment for PIK3CA-mutated breast cancer by the end of the year.
Dec 14, 2023
Pathos AI to Acquire Rain Oncology
Apr 26, 2023
Feb 3, 2023
Oct 18, 2022
Sep 23, 2022
Mar 25, 2022